Journal article
Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment
ME Vail, C Murone, A Tan, L Hii, D Abebe, PW Janes, FT Lee, M Baer, V Palath, C Bebbington, G Yarranton, C Llerena, S Garic, D Abramson, G Cartwright, AM Scott, M Lackmann
Cancer Research | Published : 2014
Abstract
Eph receptor tyrosine kinases are critical for cell-cell communication during normal and oncogenic tissue patterning and tumor growth. Somatic mutation profiles of several cancer genomes suggest EphA3 as a tumor suppressor, but its oncogenic expression pattern and role in tumorigenesis remain largely undefined. Here, we report unexpected EphA3 overexpression within the microenvironment of a range of human cancers and mouse tumor xenografts where its activation inhibits tumor growth. EphA3 is found on mouse bone marrow-derived cells with mesenchymal and myeloid phenotypes, and activation of EphA3+/CD90+/Sca1+ mesenchymal/stromal cells with an EphA3 agonist leads to cell contraction, cell-cell..
View full abstractGrants
Awarded by NHMRC
Awarded by Prostrate Cancer Foundation Australia
Funding Acknowledgements
This work was supported by grants from the NH&MRC (nos. 487922 and 1049942), Cancer Australia and Prostrate Cancer Foundation Australia (no. 491195; to M. Lackmann and A. M. Scott), The Human Frontiers Science Program (to M. Lackmann), funds from the Operational Infrastructure Support Program provided by the Victorian Government, Australia (to A. M. Scott), and KaloBios Pharmaceuticals (to M. Lackmann and A. M. Scott). M. Lackmann is an NH&MRC Senior Research Fellow.